This is particularly relevant, as the current percentage of patients with clinically actionable drivers in the Caucasian population accounts for 15–20% of non-squamous NSCLC (considering EGFR, ALK, ROS1, and BRAF), and the potential novel emerging targets might further increase this proportion. Here, ALK is linked to non-small cell lung carcinoma.